Drug Discovery USA 2026 brings together scientists from academia and industry to explore the next generation of therapeutic innovation. As advances in chemical biology and protein engineering continue to redefine what is considered “druggable,” this two-day meeting will examine how emerging modalities are expanding the boundaries of early-stage drug discovery.

The programme will highlight multifunctional small molecules –  including molecular glues, targeted protein degraders and allosteric modulators –  that enable precise control of protein stability, localisation and activity. Alongside these approaches, novel biologic strategies such as engineered antibodies, multi-specific binders, peptide scaffolds and RNA-based therapeutics are providing new ways to engage complex or transient targets with exceptional specificity.

Sessions will also explore hybrid platforms that combine the strengths of small molecules and biologics, including antibody–drug conjugates and chemically enhanced biologics, demonstrating the growing potential of synergistic therapeutic design. Together, these technologies are opening new avenues for tackling previously intractable targets and advancing precision medicine.

Guided by an expert Scientific Committee including Aled Edwards (AstraZeneca), Marija Tadin-Straps (Pfizer) and Swarna Balasubramanian (AstraZeneca), the event offers a collaborative environment for knowledge exchange, discussion and networking across the global drug discovery community.